Systemic cyclosporin treatment for high-risk corneal transplantation

Ocular Immunology and Inflammation

Volumn 4, Issue 1, 1996, Pages 15-24

  Uusitalo, Risto J ^a   Mahlberg, Kaj ^b   Krootila, Kari ^c   Ruusuvaara, Pekka ^a  

^a UNIVERSITY OF HELSINKI   (Finland)

^b Oy Leiras Finland Ab   (Finland)

^c TAMPERE UNIVERSITY HOSPITAL   (Finland)

Author keywords

Cornea; Cyclosporin A; Penetrating keratoplasty; Rejection

Indexed keywords

CORTICOSTEROID; CYCLOSPORIN A; IMMUNOSUPPRESSIVE AGENT;

ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORNEA TRANSPLANTATION; DISORIENTATION; GRAFT REJECTION; GRAFT SURVIVAL; HIGH RISK PATIENT; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; MAJOR CLINICAL STUDY; MUSCLE WEAKNESS; NAUSEA; ORAL DRUG ADMINISTRATION; PENETRATING KERATOPLASTY; SURVIVAL RATE; TREMOR;

EID: 0030052753     PISSN: 09273948     EISSN: None     Source Type: Journal    
DOI: 10.3109/09273949609069123     Document Type: Article

References (26)

1. Eye Bank Association of America. Eye Bank Association of America Annual Report: 1987-1988, Foresight 1988, 9(5); insert.
2. Alldredge OC, Krachmer JH. Clinical types of corneal transplant rejection: their manifestations, frequency, preoperative correlates, and treatment. Arch Ophthalmol 1981; 99:599-604.
3. Fine M, Stein M. The role of corneal vascularization in human corneal graft rejection. In: Jones BR (editor). Corneal Failure. Ciba Foundation Symposium 15, New Series. Amsterdam: Associated Scientific Publ. 1973; 193-208.
4. Boisjoly HM, Tourigny R, Bazin R, Laughrea PA, Dube I, Chamberland G, et al. Risk factors of corneal graft failure. Ophthalmology 1993; 100:1728-1735.
5. Maguire MG, Stark WJ, Gottsch JD, Stulting RD, Sugar A, Fink NE, Schwartz A. Risk factors for corneal graft failure and rejection in the collaborative corneal transplantation studies. Ophthalmology 1994; 101:1536-1547.
6. Vail A, Gore SM, Bradkey BA, Easty DL, Rogers CA. Corneal graft survival and visual outcome. Ophthalmology 1994; 101:120-127.
7. Brown SI, Bloomfield SE, Pearce DB. A follow-up report on transplantation of the alkali-burned cornea. Am J Ophthalmol 1973; 77:538-542.
8. Khodadoust AA, Abizadeh A. The fate of corneal regrafts after previous rejection reaction. In: Silverstein AM, O'Conner GR (editors). Immunology and Immunopathology of the Eye, New York: Masson, 1970; 167-173.
9. Borel JF, Feurer C, Gubler HU, Stähelin H. Biological effects of cyclosporin A: a new antilymphocytic agent. Agents Actions 1976; 6:468-475.
10. Hess AD, Esa AH, Colombani PM. Mechanism of action of cyclosporine: effects on cells of the immune system and on subcellular events in T cell activation. Transplant Proc 1988; 20(No 2, Suppl 2):29-40.
11. Gluckman E, Devergie A, Lokiec F. Use of cyclosporine for the prevention of graft-versus host disease after allogenic bone marrow transplantation. Transplant Proc 1988; 20(No 3, Suppl 3):461-469.
12. Berlin MW, Bouchard CS, Franz S, Chmielinska J. Topical cyclosporine in high-risk corneal transplants. Ophthalmology 1989; 96:1144-1150.
13. Williams KA Erickson SA, Coster DJ. Topical steroid, cyclosporin A, and the outcome of rat corneal allografts. Br J Ophthalmol 1987; 71:239-242.
14. Hill JC. The use of cyclosporine in high-risk keratoplasty. Am J Ophthalmol 1989; 107:506-510.
15. Hill JC. Systemic cyclosporine in high-risk keratoplasty. Short-versus long-term therapy. Ophthalmology 1994; 101:128-133.
16. Uusitalo R, Mahlberg K, Dua H, Donodo K, Gomes JAP, Oksala O. Cyclosporin A in high risk keratoplasty. Experimental and clinical data. In: Third Int Symp on Ocular Inflammation, 22-25 Ocotber 1994, Fukuoka, Japan, p 43.
17. Kruit PL, Van Baien AThM, Stilma JS. Cyclosporin A treatment in two cases of corneal peripheral melting syndrome. Doc Ophthalmol 1985; 59:33-39.
18. Masuda K, Nakajima A. A double-masked study of cyclosporin treatment in Behcet's disease. In: Schindler R (editor). Cyclosporin in Autoimmune Diseases. 1st Int Symp, Basel, March 18-20, 1985. Berlin: Springer-Verlag, 162-164.
19. Nussenblatt RP, Palestine AG, Rook AH, Scher I, Wacker WB, Gery I. Treatment of intraocular inflammatory disease with cyclosporin A. Lancet 1983; 2:235-238.
20. BenEzra D, Cohen E, Rakatomalala M, deCourten C, Harris W, Chajek T, et al. Treatment of endogenous uveitis with cyclosporin A. Transplant Proc 1988; 20(No 3, Suppl 4):122-127.
21. Vine W, Billiar T, Simmons R, Bowers LD. Cyclosporine-induced hepatotoxicity: a microassay by hepatocytes in tissue culture. Transplant Proc 1988; 20(No 3, Suppl 3):859-862.
22. Palestine AG, Austin HA III, Balow JE, Antonovych TT, Sabnis SG, Preuss HG, Nussenblatt RB. Renal histopathologic alternations in patients treated with cyclosporin for uveitis. N Engl J Med 1986; 314:1293-1298.
23. Mihatsch MJ, Thiel G, Ryffel B. Histopathology of cyclosporine nephrotoxicity. Transplant Proc 1988; 20(No 3, Suppl 3):759-771.
24. Goichot-Bonnat L, Chemal P, Pouligney Y. Cyclosporine A collyre dans la prévention du rejet de greffe de cornée à haut risque. II. Résultats cliniques post-opératoires. J Fr Ophtalmol 1987; 10:213-217.
25. Head JF, Elliott RL, McCoy JL. Evaluation of lymphocyte immunity in breast cancer patients. Breast Cancer Res Treat 1993; 26:77-88.
26. Mahlberg K, Uusitalo RJ, Gebhardt B, Kaufman HE. Prevention of experimental corneal allograft rejection in rabbits using cyclosporin collagen shields. Graefe's Arch Clin Exp Ophthalmol 1991; 229:69-74.